Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

  • LAST PRICE
    8.3200
  • TODAY'S CHANGE (%)
    -0.0200 (-0.2398%)
  • Bid / Lots
    8.2100/ 1
  • Ask / Lots
    8.5200/ 10
  • Open / Previous Close
    8.3900 / 8.3400
  • Day Range
    7.9800
    8.4000
  • 52 Week Range
    4.7100
    10.0500
  • Volume
    2,230,112

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 10:41AM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: AUPH
      10:41 AM EST, 11/07/2024 (MT Newswires) -- Aurinia Pharmaceuticals (AUPH) shares were up more than 10% in recent trading Thursday after the company reported better-than-expected Q3 net income and revenue. The company reported Q3 net income Thursday ...

    • 6:10AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: AUPH

      Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
      ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--November 07, 2024--

    • 6:00AM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: AUPH
      06:00 AM EST, 11/07/2024 (MT Newswires) -- ...

    • 6:00AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: AUPH
      2024 2023 2024 2023 ------- ------- ------- ------- (unaudited) Revenue Product revenue, net $ 55,503 $ 40,781 $158,604 $116,218 License, collaboration, and royalty revenue 12,268 13,734 16,662 14,200 ------- ------- ------- ------- Total revenue, net 67,771 54,515 175,266 130,418 ------- ------- ------- ------- Operating expenses Cost of sales 6,035 6,769 22,696 8,753 Selling, general and administrative 42,367 47,759 134,996 144,964 Research and development 3,047 13,605 12,678 39,413 Restructuring expenses -- -- 7,755 -- Other expense (income), net 4,574 2,645 159 (695) ------- ------- ------- ------- Total cost of sales and operating expenses 56,023 70,778 178,284 192,435 ------- ------- ------- ------- Income (Loss) from operations 11,748 (16,263) (3,018) (62,017) ------- ------- ------- ------- Interest expense (1,208) (1,400) (3,689) (1,465) Interest income 4,267 4,514 12,982 12,429 ------- ------- ------- ------- Net income (loss) before income taxes 14,807 (13,149) 6,275 (51,053) Income tax expense 457 298 1,952 92 ------- ------- ------- ------- Net income (loss) $ 14,350 $(13,447) $ 4,323 $(51,145) ======= ======= ======= ======= Net income (loss) per share: Basic $ 0.10 $ (0.09) $ 0.03 $ (0.36) ======= ======= ======= ======= Diluted $ 0.10 $ (0.09) $ 0.03 $ (0.36) ======= ======= ======= ======= Weighted-average common shares outstanding: Basic 143,051 142,847 143,353 143,085 Diluted 145,651 142,847 145,010 143,085 AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Nine Months Ended September 30, ------------------------ 2024 2023 -------- -------- (in thousands) (unaudited) Cash flows from operating activities Net income (loss) $ 4,323 $ (51,145) Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization 14,583 6,698 Net amortization of premiums and discounts on short-term investments (9,752) (8,836) Share-based compensation expense 22,650 33,543 Foreign exchange on finance lease liability (718) (1,335) Other, net 220 (1,659) Net changes in operating assets and liabilities Accounts receivable, net (12,394) (24,463) Inventories, net 991 (8,984) Prepaid expenses and other current assets (6,001) (2,889) Non-current operating assets (12) (16) Accounts payable, accrued and other liabilities 934 11,812 Operating lease liabilities (550) (499) -------- -------- Net cash provided by (used in) operating activities 14,274 (47,773) -------- -------- Cash flows from investing activities Purchase of investments (461,140) (379,213) Proceeds from investments 461,448 391,287 Upfront lease payment (44) (11,864) Purchase of property and equipment -- (419) Capitalized patent costs (225) (240) -------- -------- Net cash provided by (used in) investing activities 39 (449) -------- -------- Cash flows from financing activities Repurchase of common shares (18,435) -- Principal portion of finance lease payments (8,959) (3,482) Proceeds from exercise of stock options and employee share purchase plan 1,348 3,929 -------- -------- Cash (used in) provided by financing activities (26,046) 447 -------- -------- Net decrease in cash, cash equivalents, and restricted cash (11,733) (47,775) Cash, cash equivalents, and restricted cash, beginning of period 48,875 94,172 -------- -------- Cash, cash equivalents, and restricted cash, end of period $ 37,142 $ 46,397 ======== ========

    • 6:00AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: AUPH

Peers Headlines